Anti-Pfs25 human plasma reduces transmission of plasmodium falciparum isolates that have diverse genetic backgrounds

Infection and Immunity

Volumn 81, Issue 6, 2013, Pages 1984-1989

  Da, Dari F ^a,b   Dixit, Saurabh ^c   Sattabonkot, Jetsumon ^d,e   Mu, Jianbing ^c   Abate, Luc ^b   Ramineni, Bhanumati ^c   Ouedraogo, Jean Bosco ^a   MacDonald, Nicholas J ^c   Fay, Michael P ^c   Su, Xin zhuan ^c   Cohuet, Anna ^a,b   Wu, Yimin ^c  

^a Institut de Recherche en Sciences de la Santé   (Burkina Faso)

^b University de Montpellier   (France)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; MALARIA VACCINE; MONTANIDE ISA 51; PFS25; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; BURKINA FASO; CELL DENSITY; CONTROLLED STUDY; DISEASE TRANSMISSION; GAMETOCYTE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; OOCYST; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA; PLASMAPHERESIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; THAILAND;

ANIMALS; ANOPHELES; ANTIBODIES, PROTOZOAN; BURKINA FASO; GENETIC VARIATION; HUMANS; IMMUNE SERA; MALARIA VACCINES; MALARIA, FALCIPARUM; MICROSATELLITE REPEATS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; THAILAND;

EID: 84877799661     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00016-13     Document Type: Article

References (23)

1. Kaslow DC. 2002. Transmission-blocking vaccines. Chem. Immunol. 80: 287-307.
2. Birkett AJ. 2010. PATH Malaria Vaccine Initiative (MVI): perspectives on the status of malaria vaccine development. Hum. Vaccin. 6:139-145.
3. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty Fay SMP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3:e2636. doi:10.1371/journal.pone.0002636.
4. Vermeulen AN, van Deursen J, Brakenhoff RH, Lensen TH, Ponnudurai T, Meuwissen JH. 1986. Characterization of Plasmodium falciparum sexual stage antigens and their biosynthesis in synchronised gametocyte cultures. Mol. Biochem. Parasitol. 20:155-163.
5. Schneider P, Bousema T, Omar S, Gouagna L, Sawa P, Schallig H, Sauerwein R. 2006. (Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxinepyrimethamine monotherapy or in combination with artesunate. Int. J. Parasitol. 36:403-408.
6. Carter R, Graves PM, Quakyi IA, Good MF. 1989. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 169:135-147.
7. Quakyi Otoo IA, LN, Pombo D, Sugars LY, Menon A, De Groot AS, Johnson A, Alling D, Miller LH, Good MF. 1989. Differential nonresponsiveness in humans of candidate Plasmodium falciparum vaccine antigens. Am. J. Trop. Med. Hyg. 41:125-134.
8. Kaslow DC, Quakyi IA, Keister DB. 1989. Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol. Biochem. Parasitol. 32:101-103.
9. Shi YP, Alpers MP, Povoa MM, Lal AA. 1992. Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 50:179-180.
10. Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, Maslen G, O'Brien J, Djimde A, Doumbo O, Zongo I, Ouedraogo JB, Michon P, Mueller I, Siba P, Nzila A, Borrmann S, Kiara SM, Marsh K, Jiang H, Su XZ, Amaratunga C, Fairhurst R, Socheat D, Nosten F, Imwong M, White NJ, Sanders M, Anastasi E, Alcock D, Drury E, Oyola S, Quail MA, Turner DJ, Ruano-Rubio V, Jyothi D, Amenga-Etego L, Hubbart C, Jeffreys A, Rowlands K, Sutherland C, Roper C, Mangano V, Modiano D, Tan JC, Ferdig MT, Amambua-Ngwa A, Conway DJ, Takala- Harrison S, Plowe CV, Rayner JC, Rockett KA, Clark TG, Newbold CI, Berriman M, MacInnis B, Kwiatkowski DP. 2012. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 487:375-379.
11. Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A. 2005. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23:3131-3138.
12. Harris C, Morlais I, Churcher TS, Awono-Ambene P, Gouagna LC, Dabire RK, Fontenille D, Cohuet A. 2012. Plasmodium falciparum produce lower infection intensities in local versus foreign Anopheles gambiae populations. PLoS One 7:e30849. doi:10.1371/journal.pone.0030849.
13. Lehmann EL. 1999. Elements of large sample theory. Springer, New York, NY.
14. Knapp G, Hartung J. 2003. Improved tests for a random effects metaregression with a single covariate. Stat. Med. 22:2693-2710.
15. Viechtbauer W. 2010. Conducting meta-analyses in R with the metaphor Package. J. Stat. Softw. 36:1-48.
16. Morlais I, Poncon N, Simard F, Cohuet A, Fontenille D. 2004. Intraspecific nucleotide variation in Anopheles gambiae: new insights into the biology of malaria vectors. Am. J. Trop. Med. Hyg. 71:795-802.
17. Su X, Ferdig MT, Huang Y, Huynh CQ, Liu A, You J, Wootton JC, Wellems TE. 1999. A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science 286:1351-1353.
18. Liu S, Mu J, Jiang H, Su XZ. 2008. Effects of Plasmodium falciparum mixed infections on in vitro antimalarial drug tests and genotyping. Am. J. Trop. Med. Hyg. 79:178-184.
19. Churcher TS, Blagborough AM, Delves M, Ramakrishnan C, Kapulu MC, Williams AR, Biswas S, Da DF, Cohuet A, Sinden RE. 2012. Measuring the blockade of malaria transmission-an analysis of the standard membrane feeding assay. Int. J. Parasitol. 42:1037-1044.
20. Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T. 2005. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun. 73:7375-7380.
21. Okell LC, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. 2012. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat. Commun. 3:1237.
22. Billingsley PF, Medley GF, Charlwood D, Sinden RE. 1994. Relationship between prevalence and intensity of Plasmodium falciparum infection in natural populations of Anopheles mosquitoes. Am. J. Trop. Med. Hyg. 51:260-270.
23. Medley GF, Sinden RE, Fleck S, Billingsley PF, Tirawanchai N, Rodriguez MH. 1993. Heterogeneity in patterns of malarial oocyst infections in the mosquito vector. Parasitology 106:441-449.